Abstract
Background
Sector retinitis pigmentosa (RP) is an atypical form of RP in which only one or two quadrants of the retina are involved. The objectives of this study were to report the results of a molecular screening of five unrelated Chinese patients with sector RP and describe the clinical features observed in patients with RHO mutations.
Methods
Five probands that were clinically diagnosed with sector RP were recruited for genetic analysis. They underwent ophthalmic examinations, including best corrected visual acuity, fundus examination, visual field examinations, and electroretinography. A combination of molecular screening methods, including the targeted next-generation sequencing (TES) and sanger-DNA sequencing of RHO, were used to detect mutations. In silico programs were used to analyze the pathogenicity of all the variants.
Results
Three RHO missense mutations (p.T17M, p.L31Q, and p.G106R) were identified in the five unrelated probands. The novel mutation p.L31Q was detected in three unrelated probands. All patients showed bilateral and symmetrical retinal degeneration in the inferior retina and had relatively good visual acuity. Patients with the p.L31Q mutation showed phenotypic variability and variable penetrance.
Conclusion
Our results indicate that RHO mutations are also common in Chinese patients with sector RP. The RHO gene should be given priority during mutation screening analysis for Chinese patients with sector RP.
Similar content being viewed by others
Introduction
Sector retinitis pigmentosa (RP) is an atypical form of RP in which only one or two quadrants of the retina are involved [1, 2]. This disorder is characterized by regionalized areas of retinal pigment epithelium (RPE) atrophy, attenuated vessels, and bone spicule pigmentation, usually in the inferior quadrant, although affected regions in the superotemporal or superior quadrants have also been reported [1,2,3]. Sector RP is a stable or slowly progressive disorder that can appear with a subnormal or normal electroretinogram (ERG) and visual field defects of varying extent, depending on the affected regions of retina [1,2,3]. Patients may present with nyctalopia or mild visual loss, but they usually have relatively good central visual acuity unless their RP is combined with cystoid macula edema or angle-closure [1,2,3]. Most sector RP cases can be inherited in an autosomal dominant pattern and are caused by mutations of RHO [4,5,6,7,8,9].
The RHO gene, comprised of five coding exons, encodes a rod-specific protein called rhodopsin that belongs to a superfamily of seven transmembrane G-protein-coupled receptors. Rhodopsin, which has 348 amino acids, has a structure composed of three regions: the cytoplasmic, transmembrane (TM), and intradiscal domains [10,11,12]. To date, more than 150 distinct mutations (http://www.hgmd.cf.ac.uk/ac/gene.php?gene = RHO) have been identified at various sites on the RHO gene, and the majority of these are missense mutations (Human Gene Mutation Database, HGMD). Most mutations of the RHO gene have been identified in adRP patients [13, 14]. Rare mutations have been detected in autosomal recessive RP patients or dominant congenital stationary night-blindness patients, [14]. demonstrating the phenotypic variability caused by RHO mutations. Several RHO mutations have been described as being responsible for sector RP, and all of them are missense mutations, most of which are located in the intradiscal domain [4,5,6,7,8,9, 15,16,17,18].
In addition to RHO mutations, mutations of the CDH23 and USH1C genes have recently been reported to cause sector RP [19, 20]. Mutations of CDH23 and USH1C typically cause Usher syndrome (USH), an autosomal recessive disorder characterized by visual impairment because of RP, sensorineural hearing loss, and variable vestibular dysfunction. Mutations of these two genes can cause non-syndromic hearing loss as well. Unlike sector RP patients with mutations of the RHO gene, two sector RP patients with compound heterozygous mutations of CDH23 and USH1C also had hearing defects, 19, 20 which suggests that they should be diagnosed with an atypical form of USH, one inherited in an autosomal recessive pattern.
The purpose of the current study was to report the results of a molecular screening of five unrelated Chinese patients with sector RP and to describe the clinical characteristic of patients with RHO mutations.
Materials and Methods
Patients
This study was approved by the Ethics Committee of Beijing Tongren Hospital and followed the tenets of the Declaration of Helsinki. Informed consent was obtained from each enrolled patient. In this study, five unrelated probands were enlisted from the Genetics Laboratory of the Beijing Institute of Ophthalmology, Beijing Tongren Ophthalmic Center, from 2012 to 2017. Of these probands, only two had a family history of sector RP. All probands underwent detailed ophthalmic examinations, including best-corrected visual acuity with E decimal charts, slit lamp biomicroscopy, color fundus photography (TRC-NW8, TOPCON, Japan), and a visual field (VF) test, either a Humphrey visual field test (Zeiss 750i, Carl Zeiss, Ltd, Germany) or kinetic perimetry (Carl Zeiss 12187, Jena Germany). Some probands underwent full-field ERG examinations (2000NV, Chongqing Guote Medical Equipment Co. Ltd., China) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standard, fundus autofluorescence (FAF) (Heidelberg OCT SPECTRALIS, Heidelberg, Germany), and optical coherence tomography (OCT) (Heidelberg OCT SPECTRALIS, Heidelberg, Germany or Ivue-100, Optovue Inc., Fremont, CA) examinations. The diagnosis criteria for sector RP were as follows: fundus changes typical of RP in one or two quadrants bilaterally or unilaterally, normal or subnormal ERG, normal or defected visual field corresponding to the affected retinal areas, and the exclusion of any known reasons, such as trauma or infection, for the RP-like appearance of the fundus [1].
Peripheral blood samples were collected from all the probands and their available relatives for genetic analysis. The genomic DNA was then extracted using a genomic DNA extraction and purification kit (Vigorous Whole Blood Genomic DNA Extraction Kit; Vigorous, Beijing, China) based on the manufacturer’s protocol.
Targeted exome sequencing
A targeted exome sequencing (TES) panel was developed to capture 188 known inherited retinal degeneration (IRD) genes using GenCap custom enrichment kits (MyGenostics, Beijing) and following the manufacturer’s instructions, as described previously. The panel was comprised of approximately 550 kb that covered 2894 exons in total. A list of the target genes for our panel is summarized in Supplementary Table S1. The genomic DNA (1–3 µg) of two patients (019217 and 019717) was fragmented into ~300–450 base pairs and used to capture the targeted genomic sequences. The Illumina library preparation and capture experiments were performed as previously reported [21]. The enrichment libraries were sequenced on an Illumina NextSeq 500 (Illumina, Inc., San Diego, CA, USA) as 100-bp paired-end reads according to the manufacturer’s protocol. The raw sequencing data were processed for subsequent bioinformatic analysis. First, the Illumina sequencing adapters and low-quality reads were removed using fastq_mcf software. Then, the duplicated reads were removed using Picard tools (http://broadinstitute.github.io/picard/), and the high-quality reads were aligned with the reference human genome (hg19) using the Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.net/). Finally, the single nucleotide polymorphisms (SNPs) and insertions or deletions (InDels) were called using the Genomic Analysis Toolkit Haplotype Caller. The variants were further annotated by using ANNOVAR and associated with multiple databases, including 1000 genome, ESP6500, dbSNP, ExAC, and an in-house variant database (My Genostics, Beijing). Next, the alternative alleles with <5 reads and/or a frequency <30% were removed to exclude likely false-positive variants.
PCR-based sequencing of the RHO gene
All exons and flanking splicing sites of the RHO gene were amplified via the PCR in three probands (019768, 019945, and 010418). The primer sequences and related information are same as previously described [22]. PCR amplifications were performed using standard reaction mixtures, and the purified amplified fragments were sequenced using an ABI Prism 373 A DNA sequencer (Applied Biosystems, Foster City, CA, USA). A published cDNA sequence for RHO (GenBank NM_000539) was compared with the sequencing results.
Bioinformatics analysis
Two databases, HGMD (http://www.hgmd.cf.ac.uk/ac/index.php) database and the LOVD database (https://grenada.lumc.nl/LOVD2/eye/home.php), were used to screen for the mutations reported in published studies. The prediction of the pathogenicity of the variants was performed by three in silico programs, including PolyPhen2 (http://genetics.bwh.harvard.edu/pph, in the public domain), Mutation Taster (http://www.mutationtaster.org, in the public domain), and SIFT (http://sift.jcvi.org/, in the public domain). Then, we excluded the variants which had only a minor allele frequency (MAF) >0.1% in any of the databases: 1000 Genomes (http://phase3browser.1000genomes.org), Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org), and gnomAD (http://gnomad.broadinstitute.org). All the potentially pathogenic variants detected via TES were validated using Sanger sequencing. Finally, co-segregations were conducted if the DNA from the family members was available.
Results
RHO mutations
We identified three heterozygous missense mutations of the RHO genes in the five probands (Table 1). Of these mutations, the p.L31Q mutation was first identified in the current study. This novel mutation was predicted to be pathogenic by three in silico analysis programs (Polyphen2, Mutation Taster, and SIFT) and was not found in any of 100 normal controls or any public databases, including the Exome Variant Server, 1000 Genomes Database, and gnomAD. The novel mutation was identified in three unrelated probands (Table 1 and Fig. 1).
Clinical profile
Five unrelated probands harbored a heterozygous disease-causing RHO mutation, and co-segregation analyses were performed in two pedigrees (Fig. 1a). Of the five probands, only two patients had obvious symptoms: one complaint about night blindness and another whose visual acuity had gradually decreased. The other three patients were asymptomatic, and the abnormal appearance of their fundus was noted upon routine ophthalmic examination. All patients had a relatively good BCVA range, from 0.4 to 1.0 (Table 1). Color fundus photographs of the five probands revealed bilateral and symmetrical retinal degeneration in the inferior retina that included bone spicule pigmentary changes and vascular attenuation of varying extents. The visual field testing of the four probands showed superior visual field defects of varying extents, while patient 019945 presented a normal result (Table 1, Figs. 1 and 2). The FAF of three probands showed hypofluorescent regions corresponding to the affected retinal areas, with a thick curvilinear band of hyperfluorescence separating the normal central fluorescence from the affected hypofluorescent regions (Figs. 1 and 2). The horizontal cross-scan of the OCT of four probands showed a normal macular appearance. Full-field ERG recordings demonstrated the impairment of rod and cone function to varying degrees (Fig. 3).
Although the three unrelated probands carried the same mutation, p.L31Q, they showed diverse phenotypes. Proband 019217 was a 61-year-old male who had experienced nyctalopia more than 40 years and was diagnosed with angle-closure glaucoma (ACG) in his left eye <1 year ago. At his last examination, in 2012, his BCVA was 1.0 in his right eye and 0.8 in his left eye. A slit lamp examination of his eyes revealed a shallow anterior chamber. Except for regional retinal degeneration, his left eye showed a typical glaucoma optic disc appearance with a 0.9 cup/disc ratio (Fig. 1b). A co-segregation analysis revealed that his three brothers all carried the p.L31Q mutation. However, only two of his brothers (019217–2 and 019217–3) had nyctalopia and superior quadrant visual field defect complaints. The other brother (019217–1) was asymptomatic, and his color fundus photo showed mild RPE changes in the inferior retina (Fig. 1c). Probands 019717 and 019945 also carried the p.L31Q mutation and were both clinically sporadic and asymptomatic. Their ages upon their last examinations were very close. However, their retinal defect areas were quite different. Proband 019717 displayed a large area of retinal degeneration involving almost the entire inferior hemisphere, except the macular region. In contrast, proband 019945 showed small areas of RPE atrophy in the more peripheral inferior retina and had normal visual field results (Fig. 1h–j). Of the five probands, patient 019768, with mutation p.G106R, showed extensive arteriole narrowing in the affected region of the retina and the unaffected inferonasal region (Fig. 2b). Her daughter had suspicious night blindness, but she refused to undergo either ophthalmologic examination or mutation screening analysis.
Discussion
In the current study, we initially performed next-generation sequencing with our IRD panel in two patients with sector RP, and we identified one mutation of the RHO gene. Therefore, we performed the sanger-DNA sequencing of RHO in the other three patients. Three heterozygous missense mutations were identified in these five unrelated patients. Our results were consistent with the observations of several previous studies suggesting that the majority of sector RP cases may be caused by mutations of the RHO gene [2,3,4,5,6, 9, 15,16,17,18]. Although mutations of the USH1C and CDH23 genes have been described in two patients with sector RP, those patients also had early-onset hearing defects. Thus, they should be diagnosed with atypical USH [19, 20]. Consistent with our screening results, no patients in the current study had any hearing loss complaints.
Previously, nine RHO mutations have been reported to be responsible for sector RP (Table 2) [4,5,6,7,8,9, 15,16,17,18]. Most of these mutations were found in Caucasian patients, but not mutation p.G106R, which was also identified in one Japanese family [17]. It should be noted that the majority of such mutations, including the novel one identified in the current study, are located within the intradiscal domain of rhodopsin. RHO mutations have been classified into six categories based on their biochemical and cellular defects, and most of them belong to Class I or Class II [23]. Class I mutations, located exclusively at the C-terminal of the protein, can fold properly but are not correctly transported to the outer segment. Class II mutations, which occur in the intradiscal, transmembrane, and cytoplasmic domains of the protein, lead to misfolded protein being retained in the endoplasmic reticulum. Most of the previously reported mutations belong to Class II, except for two unclassified mutations, p.N15S and p.P170H [23]. Regarding the novel mutation, p.L31Q, we presume that it may have a similar pathogenic mechanism to that of the Class II mutations. However, its precise functional effect remains to be elucidated. Of the three mutations detected in the current study, p.T17M and p.G106R were first detected in Caucasian patients. Later, p.G106R was identified in a Japanese family, [17]. suggesting that these two mutations are hotspots for sector RP that are geographically widespread. In contrast, p.L31Q, which was found in three unrelated patients in the current study, was not described in patients of any other ethnic background than Chinese. Thus, we speculate that it may be a Chinese-specific mutation. The mechanism of sector RP remains unclear. Some mutations, such as p.P23H and p.G106R, can cause both typical RP and sector RP (Table 2) [13, 24]
.
Of the five pedigrees in this study, none showed a clearly autosomal dominant transmitter pattern. This was due to the fact that most patients with sector RP were asymptotic and we did not have a chance to perform detailed clinical examinations for the relatives of the five probands. This was also a limitation of the current study. The probands with the same mutation, as well as the related patients, such as the patients with pedigree 019217, showed phenotypic variability and variable penetrance. This may be related to other genetic and environmental modifiers. Chronic angle-closure glaucoma (ACG) was observed in one proband (019217) with p.L31Q. In a very early study, two sisters with sector RP were found to have ACG. Unfortunately, they did not undergo any mutation screening analysis [3]. In our one previous study, ACG was observed in two related patients with typical RP who carried the p.P347Q mutation [22]. Compared to relatively stable sector RP, ACG can cause more severe visual defects. Therefore, it should receive more attention during clinical evaluations. The relationship between ACG and RHO mutations remains unclear.
In conclusion, our results revealed that RHO mutations were also common in Chinese patients with sector RP. The RHO gene should be given priority during mutation screening analysis for Chinese patients with sector RP.
Summary
What was known before
-
RHO mutations have been described as being responsible for sector RP in Caucasion
What this study adds
-
Our results indicate that RHO mutations are also common in Chinese patients with sector RP
References
Van Woerkom C, Ferrucci S. Sector retinitis pigmentosa. Optometry. 2005;76:309–17.
Berson EL, Howard J. Temporal aspects of the electroretinogram in sector retinitis pigmentosa. Arch Ophthalmol. 1971;86:653–65.
Omphroy CA. Sector retinitis pigmentosa and chronic angle-closure glaucoma: a new association. Ophthalmologica. 1984;189:12–20.
Fishman GA, Stone EM, Sheffield VC, Gilbert LD, Kimura AE. Ocular findings associated with rhodopsin gene codon 17 and codon 182 transition mutations in dominant retinitis pigmentosa. Arch Ophthalmol. 1992;110:54–62.
Heckenlively JR, Rodriguez JA, Daiger SP. Autosomal dominant sectoral retinitis pigmentosa. Two families with transversion mutation in codon 23 of rhodopsin. Arch Ophthalmol. 1991;109:84–91.
Fishman GA, Stone EM, Gilbert LD, Kenna P, Sheffield VC. Ocular findings associated with a rhodopsin gene codon 58 transversion mutation in autosomal dominant retinitis pigmentosa. Arch Ophthalmol. 1991;109:1387–93.
Moore AT, Fitzke FW, Kemp CM, Arden GB, Keen TJ, Inglehearn CF, et al. Abnormal dark adaptation kinetics in autosomal dominant sector retinitis pigmentosa due to rod opsin mutation. Br J Ophthalmol. 1992;76:465–9.
Fishman GA, Stone EM, Gilbert LD, Sheffield VC. Ocular findings associated with a rhodopsin gene codon 106 mutation. Glycine-to-arginine change in autosomal dominant retinitis pigmentosa. Arch Ophthalmol. 1992;110:646–53.
Kranich H, Bartkowski S, Denton MJ, Krey S, Dickinson P, Duvigneau C, et al. Autosomal dominant ‘sector’ retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. Hum Mol Genet. 1993;2:813–4.
Dryja TP, McGee TL, Hahn LB, Cowley GS, Olsson JE, Reichel E, et al. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990;32:1302–7.
Dryja TP, Han LB, Cowley GS, McGee TL, Berson EL. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci USA. 1991;88:9370–4.
Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, et al. Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: Implications for the structure and function of rhodopsin. Am J Hum Genet. 1993;53:80–89.
Sohocki MM, Daiger SP, Bowne SJ, Rodriquez JA, Northrup H, Heckenlively JR, et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat. 2001;17:42–51.
Ayuso C, Millan JM. Retinitis pigmentosa and allied conditions today: a paradigm of translational research. Genome Med. 2010;2:34.
Shah SP, Wong F, Sharp DM, Vincent AL. A novel rhodopsin point mutation, proline-170-histidine, associated with sectoral retinitis pigmentosa. Opthalmic Genet. 2014;35:241–7.
Oh KT, Weleber RG, Lotery A, Oh DM, Billingslea AM, Stone EM. Description of a new mutation in rhodopsin, Pro23Ala, and comparison with electroretinographic and clinical characteristics of the Pro23His mutation. Arch Ophthalmol. 2000;118:1269–76.
Budu MM, Hayasaka S, Yamada T, Hayasaka Y. Rhodopsin gene codon 106 mutation (Gly-to-Arg) in a Japanese family with autosomal dominant retinitis pigmentosa. Jpn J Ophthalmol. 2000;44:610–4.
Napier ML, Durga D, Wolsley CJ, Chamney S, Alexander S, Brennan R, et al. Mutational analysis of the rhodopsin gene in sector retinitis pigmentosa. Ophthalmic Genet. 2015;36:239–43.
Saihan Z, Stabej PQ, Robson AG, Rangesh N, Holder GE, Moore AT, et al. Mutations in the USH1C gene associated with sector retinitis pigmentosa and hearing loss. Retina. 2011;31:1708–16.
Branson SV, McClintic JI, Stamper TH, Haldeman-Englert CR, John VJ. Sector retinitis pigmentosa associated with novel compound heterozygous mutations of CDH23. Ophthalmic Surg Lasers Imaging Retina. 2016;47:183–6.
Huang XF, Xiang P, Chen J, Xing DJ, Huang N, Min Q, et al. Targeted exome sequencing identified novel USH2A mutations in Usher syndrome families. PLoS ONE. 2013;8:e63832.
Pan Z, Lu T, Zhang X, Dai H, Yan W, Bai F, et al. Identification of two mutations of the RHO gene in two Chinese families with retinitis pigmentosa: correlation between genotype and phenotype. Mol Vis. 2012;18:3013–20.
Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med. 2005;11:177–85.
Ayuso C, Reig C, Garcia-Sandoval B, Trujillo MJ, Antinolo G, Borrego S, et al. G106R rhodopsin mutation is also present in Spanish ADRP patients. Ophthalmic Genet. 1996;17:95–101.
Acknowledgements
This work was supported by the National Key R&D Program of China, 2016YFC20160905200.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Xiao, T., Xu, K., Zhang, X. et al. Sector Retinitis Pigmentosa caused by mutations of the RHO gene. Eye 33, 592–599 (2019). https://doi.org/10.1038/s41433-018-0264-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-018-0264-3
This article is cited by
-
Genotypes and clinical features of RHO-associated retinitis pigmentosa in a Japanese population
Japanese Journal of Ophthalmology (2024)
-
Bilateral angle closure glaucoma with retinitis pigmentosa in young patients: case series
BMC Ophthalmology (2023)
-
Genotype and phenotype characteristics of RHO-associated retinitis pigmentosa in the Japanese population
Japanese Journal of Ophthalmology (2023)
-
EYS-Associated Sector Retinitis Pigmentosa
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Central Serotonergic Trophic Support of the Retina: Its Impairment in Retinitis Pigmentosa (in an Animal Model and in Clinics)
Neurophysiology (2021)